跳至主要内容
临床试验/CTRI/2023/08/057144
CTRI/2023/08/057144招募中2 期

A pilot randomized controlled clinical trial to evaluate thehepatoprotective effect of Liv-Ever (Punarnava – Boerhaviadiffusa -tablet) in patients with elevated liver enzyme panel

University of Kerala1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2023年6月9日最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
45
试验地点
1
主要终点
To evaluate the hepatoprotective effect of LIV-EVER (Punarnava – Boerhavia diffusa

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Subjects of either gender with an age group between
  • 70 years Subjects having elevated liver enzymes panel due to multiple causes like obesity, hyper triglyceridemia, drug induced liver disease etc. Subjects with fluctuating liver enzyme panel due to unknown reasons. Subjects who are willing to sign the informed consent form.

排除标准

  • Patients with chronic liver diseases Pregnant and lactating women Suspected malignant conditions.

结局指标

主要结局

To evaluate the hepatoprotective effect of LIV-EVER (Punarnava – Boerhavia diffusa

时间窗: The assessments will be done on done on 0th | , 45th and 90th day and the results obtained will be | statistically analyzed to evaluate the hepatoprotective effect of trial drug in elevated liver enzyme | panels.

L-tablet ) in patients with elevated liver enzyme panel

时间窗: The assessments will be done on done on 0th | , 45th and 90th day and the results obtained will be | statistically analyzed to evaluate the hepatoprotective effect of trial drug in elevated liver enzyme | panels.

次要结局

  • To evaluate the additional therapeutic benefits of LIV-EVER (Punarnava – Boerhavia(diffusa L –tablet) in patients with elevated liver enzyme panel.)

研究者

发起方
University of Kerala
申办方类型
Other [Govt University]

研究点 (1)

Loading locations...

相似试验